Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Short-term Investments (2017 - 2025)

Phibro Animal Health (PAHC) has 9 years of Short-term Investments data on record, last reported at $19.0 million in Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $19.0 million; the TTM value through Dec 2025 reached $19.0 million, changed N/A, while the annual FY2025 figure was $9.0 million, 79.55% down from the prior year.
  • Short-term Investments reached $19.0 million in Q4 2025 per PAHC's latest filing, up from $12.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $59.5 million in Q4 2023 and bottomed at $2.6 million in Q3 2021.
  • Average Short-term Investments over 5 years is $29.1 million, with a median of $38.0 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: plummeted 95.68% in 2021, then surged 495.23% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $2.6 million in 2021, then skyrocketed by 279.65% to $10.0 million in 2022, then soared by 495.23% to $59.5 million in 2023, then tumbled by 36.16% to $38.0 million in 2024, then tumbled by 49.94% to $19.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $19.0 million in Q4 2025, $12.5 million in Q3 2025, and $9.0 million in Q2 2025.